By Dean Seal
Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.
The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.
The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.
This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 20, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。